Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer : Should I Get the Covid-19 Vaccine While Pregnant or Breastfeeding? Experts Explain the Safety, Evidence and Clinical Trials

08/02/2021 | 06:06am EDT

Since the COVID-19 pandemic began, public health communications put a special focus on helping high-risk populations, such as seniors, stay safe. Yet, information for pregnant or breastfeeding individuals has been inconsistent and hard to find.

Though most pregnant people who become ill with COVID-19 have mild symptoms, pregnancy does increase the risk of being admitted to hospital and intensive care, as well as the risk of preterm birth and dangerously high blood pressure.

Currently, all Canadian provinces and territories offer COVID-19 vaccines to eligible pregnant individuals. However, inconsistent information can lead to confusion among those looking to make informed decisions about vaccination for themselves and their families.

We research vaccination in pregnant populations, including ways to improve consistency in information. For example, information about vaccination during pregnancy contained in vaccine package inserts approved by Health Canada may differ from the recommendations of the Canadian National Advisory Committee on Immunization (NACI).

Exclusion from trials

Inconsistencies in information about COVID-19 vaccination arose because pregnant and breastfeeding people were initially excluded from gold-standard randomized clinical trials. Experts in reproductive health, vaccination and medicine have developed guidelines for ethically including pregnant and breastfeeding people in vaccine development and deployment. These guidelines were available before the COVID-19 pandemic and could have informed early COVID-19 vaccine development.

The reasons for excluding pregnant and breastfeeding people from trials are complex. They may include fear or legal concerns about harming the fetus or infant. In the case of COVID-19 vaccines, the "need for speed" made clinical development the top priority. That meant proceeding with trials before completing the pre-clinical requirements for involving pregnant participants in clinical trials. These prerequisites include animal studies on the effects of COVID-19 vaccines on fetal development and reproduction.

Exclusion from trials has created inconsistencies between international recommendations, national policies and vaccine eligibility and prioritization in different provinces (Alberta, Ontario and Québec) about COVID-19 vaccination while pregnant or breastfeeding.

Inconsistent messages

Since May 2021, NACI has recommended COVID-19 vaccination for pregnant or breastfeeding people. However, gaps in data contributed to caution regarding COVID-19 vaccination during pregnancy in NACI's initial recommendations. In contrast, the Society of Obstetricians and Gynaecologists of Canada (SOGC) and other expert advisory bodies in maternal health recommended that pregnant people were offered the vaccines from the outset.

As more information became available demonstrating the safety of vaccination in pregnancy, these guidelines have been updated and are now more closely aligned.

Clinical trials on mRNA vaccination in pregnancy are underway, including at the U.S. National Institutes of Health and Pfizer/BioNTech). AstraZeneca and Johnson & Johnson had planned clinical trials in pregnancy, but they are paused pending investigation into risks of a rare form of blood clot. It will be several months before any trial data become available, long after most Canadians will have made their decisions about COVID-19 vaccination.

The highest quality evidence should have been available to inform vaccine policies, recommendations and individuals' decisions about whether to receive a vaccine while pregnant or breastfeeding.

Health-care and other essential workers who were pregnant or breastfeeding had a difficult decision to make. They had to weigh the known dangers of COVID-19 against uncertainties about vaccine safety information in the early weeks of vaccine rollout. Exclusion from clinical trials left these front-line workers to make decisions about COVID-19 vaccines based on incomplete information.

Good quality information is now available

Evidence is now available to show that COVID-19 vaccines are safe for people who are pregnant or breastfeeding and their infants. More than 130,000 people who received COVID-19 vaccines while pregnant or breastfeeding have joined the V-safe registry in the United States. Most received Pfizer/BioNTech or Moderna mRNA vaccines. Initial findings from that registry have been published, showing no safety concerns so far.

Recent studies also suggest that after vaccination, COVID-19 antibodies can cross the placenta and also pass into breast milk and may protect the infant.

For pregnant or breastfeeding people seeking information, SOGC offers answers to COVID-19 vaccine Frequently Asked Questions, a detailed statement about vaccination in pregnancy and other resources. Local and provincial public health and maternal health programs have also developed information to help pregnant or breastfeeding individuals make informed decisions about COVID-19 vaccination.

Long-term followup

There is a need for long-term followup of people vaccinated in early stages of pregnancy and their infants. Public Health and researchers in Canada continue to monitor pregnant individuals who have received a COVID-19 vaccine. Pregnant and breastfeeding individuals can sign up to participate in these programs: Canadian COVID-19 Vaccine Registry for Pregnant and Lactating Individuals and the Canadian National Vaccine Safety Network COVID study.

Earlier access to data about vaccination while pregnant or breastfeeding is needed to develop equitable public health guidelines. Pregnant and breastfeeding people include front-line workers at greater risk of exposure to COVID-19 and other viruses.

About 70 per cent of the world's health and social care workers are women, many of whom are of reproductive age. In Canada, visible minorities, immigrants and women are over-represented among nurse aides, orderlies and patient service associates who may be prioritized for vaccination.

As we take stock of our response to this pandemic, it is important to consider the implications of excluding pregnant and breastfeeding people from clinical trials and consider how we can do better next time.

Do you have a question about COVID-19 vaccines? Email us at ca?vaccination@theconversation.com and vaccine experts will answer questions in upcoming articles.

Terra Manca, Postdoctoral Fellow, Canadian Center for Vaccinology (IWK Health Centre); Department of Pediatrics, Dalhousie University and Karina A Top, Associate Professor, Department of Pediatrics, Dalhousie University

Copyright The Conversation Africa. Distributed by AllAfrica Global Media (allAfrica.com)., source News Service English

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 3.67% 352.67 Delayed Quote.316.17%
PFIZER, INC. 1.37% 44.505 Delayed Quote.19.32%
All news about PFIZER, INC.
10:18aVC DAILY : Biotechs Seek New Skill Set From -2-
10:03aPFIZER : Invites Public to View and Listen to Webcast of Pfizer November 2 Conference Call..
10:00aWALL STREET STOCK EXCHANGE : As smooth as silk
09:32aPFIZER : Thinking about trading options or stock in Ambarella, General Motors, Plug Power,..
08:05aENDO INTERNATIONAL : Launches First and Only Generic Version of Chantix (varenicline) Tabl..
08:05aPFIZER : FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Popul..
08:05aPFIZER : Department of Health and Social Care - UK vaccine swap with South Korea in joint ..
08:05aPFIZER : Declares Fourth-Quarter 2021 Dividend
08:03aPFIZER : Gsk - ViiV Healthcare to present key data that provides further support for the u..
06:37aEUROPEAN MIDDAY BRIEFING : European Stocks Rise -2-
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 111 M - -
Net income 2021 18 438 M - -
Net Debt 2021 28 980 M - -
P/E ratio 2021 13,0x
Yield 2021 3,59%
Capitalization 246 B 246 B -
EV / Sales 2021 3,40x
EV / Sales 2022 4,01x
Nbr of Employees 78 500
Free-Float 59,3%
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 20
Last Close Price 43,95 $
Average target price 45,08 $
Spread / Average Target 2,57%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Chief Scientific Officer & Research President
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.19.32%246 414
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
NOVO NORDISK A/S50.62%232 291
ABBVIE INC.-0.69%188 045